A federal appeals court on Thursday rejected Eli Lilly’s appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid. The 7th ...

Tribeca Studios has launched a new incubator program, which aims to empower rising filmmakers to more earnestly portray diseases and health-related stories on-screen. Tribeca created the program with ...

Sept 9 (Reuters) - Drugmaker Eli Lilly (LLY.N), opens new tab said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug ...

Eli Lilly has developed artificial intelligence models that can help predict the behavior of potential drug candidates, based on the data the drugmaker has collected over the last two decades and at ...

Lila Biologics, a startup that spun out of Nobel Laureate David Baker’s lab at the University of Washington, announced a collaboration with pharmaceutical giant Eli Lilly to develop therapies for ...

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio. Lilly stock popped ...

Eli Lilly is releasing new Phase 3 trial results Tuesday. Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall ...

Press Secretary Karoline Leavitt read President Trump’s letter to several pharmaceutical companies, which asked them to provide ‘American families immediate relief from the vastly inflated drug prices ...

Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal's lead candidate not part of deal with Lilly Aug 14 (Reuters) - Eli ...